The investigation launched with the Competition Board decision dated 11.09.2025 and numbered 25-34/810-474 on some undertakings, most of which operate in the pharmaceutical sector, for violating Article 4 of the Act no 4054 by participating in a no-poach agreement and/or exchanging competitively sensitive information has been concluded. Of the undertakings that were found to have participated in the infringement, Adeka İlaç Sanayi ve Ticaret AŞ, Amgen İlaç Ticaret Ltd. Şti, Argis İlaç Sanayi ve Ticaret AŞ, Arven İlaç Sanayi ve Ticaret AŞ, AstraZeneca İlaç Sanayi ve Ticaret Ltd Şti, Berko İlaç ve Kimya Sanayi AŞ, Farmatek İlaç Sanayi Ticaret AŞ, Helba İlaç İç ve Dış Sanayi Ticaret AŞ, İlko İlaç Sanayi ve Ticaret AŞ, Merck İlaç Ecza ve Kimya Ticaret AŞ, Novartis Sağlık, Gıda ve Tarım Ürünleri Sanayi ve Ticaret AŞ, Novo Nordisk Sağlık Ürünleri Ticaret Ltd Şti, Pfizer PFE İlaçları AŞ, Sanofi İlaç Sanayi ve Ticaret AŞ, Sanovel İlaç Sanayi ve Ticaret AŞ, Santa Farma İlaç Sanayi AŞ and Servier İlaç ve Araştırma AŞ were imposed administrative fines of 244.801.302,91 TL in total.

No-poach agreements are direct or indirect agreements between rivals that compete for labor not to recruit employees from each other. No-poach agreements may have different forms and scope. In addition, competition law defines information exchange as the unilateral or mutual sharing of commercial information which affects or may potentially affect the strategic behavior and decisions of the competitors among actors operating in the same market. The investigation examined the exchange of competitively sensitive information on future employee wages and benefits, and decided that the practices concerned constituted an infringement of competition.

The investigation determined that Adeka İlaç Sanayi ve Ticaret AŞ, Argis İlaç Sanayi ve Ticaret AŞ, Arven İlaç Sanayi ve Ticaret AŞ, Berko İlaç ve Kimya Sanayi AŞ, Farmatek İlaç Sanayi Ticaret AŞ, Helba İlaç İç ve Dış Sanayi Ticaret AŞ, İlko İlaç Sanayi ve Ticaret AŞ, Sanovel İlaç Sanayi ve Ticaret AŞ, Santa Farma İlaç Sanayi AŞ and  Servier İlaç ve Araştırma AŞ engaged in no-poach agreements and/or concerted practices.

On the other hand, it was found that Amgen İlaç Ticaret Ltd. Şti., AstraZeneca İlaç Sanayi ve Ticaret Ltd. Şti., Merck İlaç Ecza ve Kimya Ticaret AŞ, Novartis Sağlık, Gıda ve Tarım Ürünleri Sanayi ve Ticaret AŞ, Novo Nordisk Sağlık Ürünleri Ticaret Limited Şirketi, Pfizer PFE İlaçları AŞ and Sanofi İlaç Sanayi ve Ticaret AŞ exchanged competitively sensitive information on future employee wages and benefits.